Copyright © Inderes 2011 - present. All rights reserved.

Novo Nordisk

247.90 DKK

-0.30 %

Less than 1K followers

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

-0.30 %
-11.67 %
-23.78 %
-19.93 %
-29.17 %
-60.74 %
-50.87 %
+16.09 %
+19,811.65 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.11T DKK
Turnover
1.61B DKK
Revenue
309.06B
EBIT %
41.3 %
P/E
10.75
Dividend yield-%
4.72 %
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.3
2026

General meeting '26

27.3
2026

Half year dividend

6.5
2026

Interim report Q1'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Eli Lilly really knows how to do this. They’ll definitely win this comparison, as they aren’t going up against the p.o. semaglutide dose for obesity indication (the 25mg strength), but rather the 14mg diabetes dose. They’re quite cleverly and certainly leading people astray on purpose...
2/26/2026, 8:36 PM
by JNivala
48
Tärkeimmät talousuutiset | Kauppalehti – 25 Feb 26 Novo Nordisk and Vivtex partner to develop next-generation oral medicines for... Tärkeimmät ajankohtaiset talousuutiset, pörssikurssit ja kattavat sijoittajapalvelut löydät Kauppalehdestä. Novo Nordisk and Vivtex partner to develop...
2/25/2026, 1:25 PM
by Index
32
Novo announced that the US FDA approved a growth hormone named Sogroya for new indications. The drug is injected only once a week, meaning not every day, and it can now be used for children over 2.5 years old for certain “causes” of short stature, as well as for both children and...
2/28/2026, 8:14 PM
by Sijoittaja-alokas
29
It’s funny how differently these two companies communicate. Novo reports with almost autistic honesty, even digging its own grave and praising its competitor at the same time—disadvantageously for its own business—while Eli Lilly deliberately seeks to create misleading impressions...
2/26/2026, 8:56 PM
29
Narratives and news dominate a lot of the information space. Writing on a phone (may contain errors) from a slightly different angle. The idea started from this comment regarding Nurminen’s cash flow: It is well known that Novo has invested heavily in new factories and R&D in 2024...
2/27/2026, 8:10 AM
by Deep Value
19
It’s trivialities, whether these have to be taken on an empty stomach and washed down with water. I wonder how severe an eating disorder one must have to not be able to go without eating for half an hour in order to take their medication. After all, human life is typically not constant...
2/25/2026, 1:15 PM
13
More blows to the face for Novo. Benzinga Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and... For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3In a key secondary endpoint, participants on...
2/26/2026, 8:18 PM
9
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.